Becton Dickinson (BDX) has been the subject of significant attention in the recent period. The company has seen a
rebound in its share price, and announced a
CFO transition. Remarkably, the company announced its plans to increase its
dividend to $1.05. However, insider Michael Feld sold his shares, raising some speculation. Notably,
Morgan Stanley maintained its buy rating and
raised the target price to $210. Becton Dickinson also announced a strategic
partnership with ChemoGLO to accelerate hazardous drug surface testing to 10 minutes. Further, for the 54th consecutive year, the
BD board increased the dividend. There is a valuation evaluation after the
European launch of Surgiphor and multiple strategic initiatives. BD also
add two independent directors to its board and expands its membership. Becton Dickinson and BDX have shown a
bull case shift following the release of Europe's first CE-approved surgical irrigation system. There are also credible analyses pointing to Becton Dickinson as a strong and durable
long-term investment. The recent execution of AI-enabled solutions to improve health care connectivity also demonstrates the continuous innovation of BDX and the potential for the company's ongoing growth and valuation.
Becton Dickinson and BDX News Analytics from Thu, 03 Apr 2025 07:00:00 GMT to Sat, 06 Dec 2025 07:35:08 GMT -
Rating 6
- Innovation 7
- Information 8
- Rumor 3
